A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age

Janssen Vaccines and Prevention B.V.0 个研究点目标入组 48 人开始时间: 2019年4月12日最近更新: 2022年3月21日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 48

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Each potential subject must satisfy all of the following criteria to be enrolled in the study:
•1. Each subject’s parent(s)/legal guardian(s) must sign an informed consent form (ICF) indicating that he/she understands the purpose of and procedures required for the study, are willing for his/her child to participate in the study and attend all scheduled visits, and are willing and able to comply with all study procedures, including maintaining contact with the site for 2 RSV seasons following the first dose, and adhere to the prohibitions and restrictions specified in this protocol.
•Note: For each subject, at least one parent or legal guardian, according to local regulations, must give written consent.
•2. Subject is male or female, whose age on the day of ICF signature is =12 months to =24 months and who is seronegative for RSV within 42 days prior to dosing.
•Note: Serostatus may be assessed via the RSV enzyme immunoassay (EIA) if available from a different study. If done within 42 days of first dose, this assessment would not have to be repeated in the absence of a history of respiratory infection during that period.
•3. Subject is the product of a normal term pregnancy =37 weeks, with a minimum birth weight of 2.5 kilogram (kg).
•4. Subject must be in good health without any significant medical illness on the basis of physical examination, medical history, and vital signs performed at screening.
•5. Subject has received all routine immunizations appropriate for his or her age according to local guidelines.
•6. Each subject’s parent(s)/legal guardian(s) must have access to a consistent means of contact either by telephone contact or email/computer.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 48
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Any potential subject who meets any of the following criteria will be excluded from participating in the study:
•1. Subject has moderate or severe illness (this does not include minor illnesses such as diarrhea) or temperature =38.0 ºC within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted.
•2. Any subject who has had an respiratory tract infection (RTI) between screening and randomization that the principal investigator(s) [PI(s)] feels would make them ineligible.
•3. Subject’s weight is below 10th percentile according to World Health Organization (WHO) pediatric growth and weight charts.
•4. Subject has any clinically significant acute or chronic medical condition (eg, history of seizure disorders, bleeding/clotting disorder, autoimmune disease, active malignancy, systemic infections, congenital heart disease, history of any pulmonary condition requiring medication, atopy, reactive airway disease, medically-confirmed wheezing, bronchoconstriction or treatment with a ß2 agonist, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease, medically-confirmed apnea, hospitalization for respiratory illness, or mechanical ventilation for respiratory illness) that, in the opinion of the investigator, would preclude participation.
•5. Subject has major congenital anomalies (after discussion with the study responsible physician/ scientist [SRP/S]) or known cytogenetic disorders (eg, Down’s syndrome).
•6. Subject has had major surgery within the 4 weeks prior to randomization or has planned major surgery through the course of the study.
•7. Subject is in receipt of, or planning to receive, live attenuated vaccine (eg, measles, mumps and rubella [MMR] or varicella, but excluding rotavirus vaccine) within 28 days of each study vaccination (ie, before and after); other vaccines (eg, influenza, pertussis, polio or rotavirus) should be given at least 14 days before or 14 days after each study vaccination.
•Note: Planning for routine childhood vaccinations will be available from the site to ensure that these can be taken at appropriate times during the study.
•8. Subject has known or suspected immunodeficiency, such as known human immunodeficiency virus (HIV) infection.
•9. Subject has received an investigational drug or used an invasive investigational medical device within 30 days or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during this study.
•Note: Participation in an observational clinical study (ie, with no intervention) is allowed upon approval of the sponsor.
•10. Subject has a known allergy to vaccines or vaccine components (including any of the constituents of the study vaccine), or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components (including any of the constituents of the study vaccine). Note: subjects with egg allergies can be enrolled.
•11. Subject has a history of the following moderate to severe chronic conditions: urticaria (recurrent hives), eczema and/or atopic dermatitis.
•12. Subject has a history of acute polyneuropathy (eg, Guillain-Barré syndrome).
•13. Subject has chronic or recurrent use of immunomodulators/suppressors, eg, cancer chemotherapeutic agents, oral or parenteral corticosteroids for at least 5 days within 42 days prior to randomization, or planned during the study.

研究者

发起方

Janssen Vaccines and Prevention B.V.

相似试验

进行中（未招募）

1 期

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in respiratory syncytial virus (RSV)-seronegative ToddlersProphylactic respiratory syncytial virus (RSV)MedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestations

EUCTR2017-003859-36-FIJanssen Vaccines and Prevention B.V.36

进行中（未招募）

1 期

EUCTR2017-003859-36-SEJanssen Vaccines and Prevention B.V.48

进行中（未招募）

1 期

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in respiratory syncytial virus (RSV)-seronegative Toddlers

EUCTR2017-003859-36-GBJanssen Vaccines and Prevention B.V.36

进行中（未招募）

1 期

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in respiratory syncytial virus (RSV)-seronegative Toddlers

EUCTR2017-003859-36-PLJanssen Vaccines and Prevention B.V.48

进行中（未招募）

1 期

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in respiratory syncytial virus (RSV)-seronegative ToddlersProphylactic respiratory syncytial virus (RSV)MedDRA version: 20.1 Level: PT Classification code 10061603 Term: Respiratory syncytial virus infection System Organ Class: 10021881 - Infections and infestations

EUCTR2017-003859-36-DEJanssen Vaccines and Prevention B.V.48